tetano
Editor, Senior Moderator
Clin Transl Sci. 2020 Apr 21. doi: 10.1111/cts.12805. [Epub ahead of print]
Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.
Zhou Y[SUP]1[/SUP], Han T[SUP]2[/SUP], Chen J[SUP]1[/SUP], Hou C[SUP]1[/SUP], Hua L[SUP]1[/SUP], He S[SUP]1[/SUP], Guo Y[SUP]1[/SUP], Zhang S[SUP]1[/SUP], Wang Y[SUP]1[/SUP], Yuan J[SUP]1[/SUP], Zhao C[SUP]1[/SUP], Zhang J[SUP]1[/SUP], Jia Q[SUP]1[/SUP], Zuo X[SUP]2[/SUP], Li J[SUP]2[/SUP], Wang L[SUP]1[/SUP], Cao Q[SUP]2[/SUP], Jia E[SUP]1[/SUP].
Author information
Abstract
We aimed to report the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by SARS-CoV-2. The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory-confirmed severe and critical cases of COVID-19 from the intensive care unit (ICU) ward of the Huangshi Central Hospital, Hubei Province, China were investigated. A total of 21 patients (13 males and eight females) including eight (38.1%) severe cases and 13 (61.9%) critical cases were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most of them (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest CT were ground-glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurements were lymphocytopenia (85.7%), elevated levels of C-reactive protein (94.7%), and Interleukin-6 (89.5%). The prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibody in the cases was 20%, 25% and 50% respectively. In the present work, we retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases with COVID-19. Autoimmune phenomena exist in COVID-19 subjects, and the results provide the rationale for a strategy of prevention of dysfunction of immune and optimal immunosuppressive therapy in the future.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Autoimmune characteristics; Clinical characteristics; Coronavirus disease-19 (COVID-19); SARS-CoV-2; Severe and critical cases
PMID:32315487DOI:10.1111/cts.12805
Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.
Zhou Y[SUP]1[/SUP], Han T[SUP]2[/SUP], Chen J[SUP]1[/SUP], Hou C[SUP]1[/SUP], Hua L[SUP]1[/SUP], He S[SUP]1[/SUP], Guo Y[SUP]1[/SUP], Zhang S[SUP]1[/SUP], Wang Y[SUP]1[/SUP], Yuan J[SUP]1[/SUP], Zhao C[SUP]1[/SUP], Zhang J[SUP]1[/SUP], Jia Q[SUP]1[/SUP], Zuo X[SUP]2[/SUP], Li J[SUP]2[/SUP], Wang L[SUP]1[/SUP], Cao Q[SUP]2[/SUP], Jia E[SUP]1[/SUP].
Author information
Abstract
We aimed to report the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by SARS-CoV-2. The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory-confirmed severe and critical cases of COVID-19 from the intensive care unit (ICU) ward of the Huangshi Central Hospital, Hubei Province, China were investigated. A total of 21 patients (13 males and eight females) including eight (38.1%) severe cases and 13 (61.9%) critical cases were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most of them (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest CT were ground-glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurements were lymphocytopenia (85.7%), elevated levels of C-reactive protein (94.7%), and Interleukin-6 (89.5%). The prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibody in the cases was 20%, 25% and 50% respectively. In the present work, we retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases with COVID-19. Autoimmune phenomena exist in COVID-19 subjects, and the results provide the rationale for a strategy of prevention of dysfunction of immune and optimal immunosuppressive therapy in the future.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Autoimmune characteristics; Clinical characteristics; Coronavirus disease-19 (COVID-19); SARS-CoV-2; Severe and critical cases
PMID:32315487DOI:10.1111/cts.12805